This protein, which can build up right into a ‘plaque’, is normally thought to be toxic to human brain cells and to prevent them from functioning properly. Seventy-eight participants with early stage Alzheimer’s disease took either 50mg or 250mg dosages of the medication PBT2, or a placebo, during the period of 12 weeks in a randomised, double-blind clinical trial, led by a researcher from Imperial College London working with colleagues in Australia and Sweden. Both doses of PBT2 capsules were observed to be secure and well tolerated during the course of the study. Participants undertook several exams to assess their cognitive function, prior to starting treatment and at the final end of the 12-week period.The trial recruited 5,380 patients from 898 centers in 49 countries and randomized them to get alogliptin or placebo, administered in a double-blind style along with standard-of-care treatment for type 2 diabetes mellitus and cardiovascular risk factors. Related StoriesDiabetes prevention starts in the wombStudy finds high prevalence of dehydration in older people living in UK care homesBariatric surgery improves fat, metabolic health and quality of life in adolescents after three years Due to its renal clearance, alogliptin dosing was altered according to kidney function, with 71.4 percent of patients receiving 25 mg, 25.7 percent receiving 12.5 mg, and 2.9 percent getting 6.25 mg daily. After a median follow-up of 18 months, and up to 40 months, the primary endpoint, which was a composite of cardiovascular loss of life, myocardial infarction, and stroke acquired occurred at an identical price in alogliptin and placebo-treated patients .